{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:43:49Z","timestamp":1790667829293,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00404-019-05395-3","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T10:03:57Z","timestamp":1574935437000},"page":"273-281","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Feasibility of a large multi-center translational research project for newly diagnosed breast and ovarian cancer patients with affiliated biobank: the BRandO biology and outcome (BiO)-project"],"prefix":"10.1007","volume":"301","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8273-9906","authenticated-orcid":false,"given":"Amelie","family":"De Gregorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Schlicht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Flock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"K\u00fchn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Felberbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"De Gregorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Wolfram Paul","family":"Friedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wiesm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Janni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Rothenbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"3","key":"5395_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ygyno.2011.02.014","volume":"121","author":"P Harter","year":"2011","unstructured":"Harter P, Muallem ZM, Buhrmann C et al (2011) Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol 121(3):615\u2013619. https:\/\/doi.org\/10.1016\/j.ygyno.2011.02.014","journal-title":"Gynecol Oncol"},{"issue":"4","key":"5395_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jamcollsurg.2009.01.006","volume":"208","author":"GD Aletti","year":"2009","unstructured":"Aletti GD, Dowdy SC, Gostout BS et al (2009) Quality improvement in the surgical approach to advanced ovarian cancer: the mayo clinic experience. J Am Coll Surg 208(4):614\u2013620. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2009.01.006","journal-title":"J Am Coll Surg"},{"issue":"10","key":"5395_CR3","doi-asserted-by":"publisher","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter P, Hauke J, Heitz F et al (2017) Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE 12(10):e0186043. https:\/\/doi.org\/10.1371\/journal.pone.0186043","journal-title":"PLoS ONE"},{"key":"5395_CR4","unstructured":"Robert Koch-Institut. Zentrum F\u00fcr Krebsregisterdaten\u2014Brustkrebs (2014) https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Brustkrebs\/brustkrebs_node.html. Accessed 2 Apr 2018"},{"issue":"5","key":"5395_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/cancers11050664","volume":"11","author":"N Eiro","year":"2019","unstructured":"Eiro N, Gonzalez LO, Fraile M, Cid S, Schneider J, Vizoso FJ (2019) Breast cancer tumor stroma: cellular components, phenotypic heterogeneity, intercellular communication, prognostic implications and therapeutic opportunities. Cancers (Basel) 11(5):664. https:\/\/doi.org\/10.3390\/cancers11050664","journal-title":"Cancers (Basel)"},{"issue":"26","key":"5395_CR6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"issue":"8","key":"5395_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J et al (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753\u2013763. https:\/\/doi.org\/10.1056\/NEJMoa1802905","journal-title":"N Engl J Med"},{"issue":"6","key":"5395_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"3","key":"5395_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ygyno.2015.12.027","volume":"140","author":"P Harter","year":"2016","unstructured":"Harter P, Johnson T, Berton-Rigaud D et al (2016) BRCA1\/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol 140(3):443\u2013449. https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.027","journal-title":"Gynecol Oncol"},{"issue":"6797","key":"5395_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"},{"issue":"3","key":"5395_CR11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000489329","volume":"13","author":"C Liedtke","year":"2018","unstructured":"Liedtke C, Jackisch C, Thill M et al (2018) AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2018. Breast Care 13(3):196\u2013208. https:\/\/doi.org\/10.1159\/000489329","journal-title":"Breast Care"},{"issue":"20","key":"5395_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G et al (2019) Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"N Engl J Med"},{"issue":"3","key":"5395_CR13","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","volume":"2","author":"TJ Key","year":"2001","unstructured":"Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2(3):133\u2013140. https:\/\/doi.org\/10.1016\/S1470-2045(00)00254-0","journal-title":"Lancet Oncol"},{"key":"5395_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ctro.2018.10.001","volume":"13","author":"KA Kessel","year":"2018","unstructured":"Kessel KA, Vogel MME, Kessel C et al (2018) Cancer clinical trials\u2014survey evaluating patient participation and acceptance in a university-based comprehensive cancer center (CCC). Clin Transl Radiat Oncol 13:44\u201349. https:\/\/doi.org\/10.1016\/j.ctro.2018.10.001","journal-title":"Clin Transl Radiat Oncol"},{"issue":"1","key":"5395_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13063-015-1105-3","volume":"17","author":"SY Moorcraft","year":"2016","unstructured":"Moorcraft SY, Marriott C, Peckitt C et al (2016) Patients\u2019 willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials 17(1):17. https:\/\/doi.org\/10.1186\/s13063-015-1105-3","journal-title":"Trials"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-019-05395-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-019-05395-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:07:54Z","timestamp":1606435674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-019-05395-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5395"],"URL":"https:\/\/doi.org\/10.1007\/s00404-019-05395-3","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"21 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JH: Celgene. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study protocol and patient informed consent have been approved by the local ethic committee and are in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}